Teratogenicity of Antibacterial Agents by Mirela Erić & Ana Sabo
Coll. Antropol. 32 (2008) 3: 919–925
Original scientific paper
Teratogenicity of Antibacterial Agents
Mirela Eri}1 and Ana Sabo2
1 Department of Anatomy, School of Medicine, University of Novi Sad, Serbia
2 Department of Pharmacology, Toxicology and Clinical Pharmacology, School of Medicine, University of Novi Sad, Serbia
A B S T R A C T
The aim of our study was to study the possible correlation between use of antibacterial drugs in pregnancy and occur-
rence of congenital malformations. Among 6099 investigated pregnant women, 392 (6.43%) used antibacterial drugs.
The most frequently used antibacterials belonged to category B (75.77%), while 14.54% antibiotics belonged to category D
and 1.02% to category X. The most often used antibiotics were cephalexin (22.19%), amoxicillin (20.66%) and ampicillin
(14.29%). In 14 embryos exposed to effects of beta-lactams in utero, malformations were detected. The results of this study
show possible teratogenic potential even with those antibacterials which are considered safe, but as those are usually mi-
nor malformations, they often pass undetected. Because of that and because of frequent use of antibacterials during
pregnacy, detailed examinations concerning their safety should be made.
Key words: antibiotics, adverse effects, pregnancy+drug effects, pregnancy complications, fetus+drug effects, tera-
togens, abnormalities
Introduction
An International multicentric study entitled Collabo-
rative Study on Drug Use in Pregnancy (DUP) was initi-
ated in 1987 by the Mario Negri Institute (Milano) and
co-sponsored by the WHO Regional Office for Europe
(Copenhagen). There were 22 countries involved in 4
continents, among which two centers from former Yugo-
slavia: Zagreb and Novi Sad. The study covered drug use
in pregnancy and puerperium. Novi Sad participated
with 296 questionnaires performed on pregnant women,
who were admitted to the Clinic for delivery. The pre-
scription of some medicines in the Centre of Novi Sad
was found to be at the extreme, mainly in the post-
partum period. Therefore educational efforts were made
in order to improve prescribing habits, and 10 years later,
considerable improvements were seen. However, this sam-
ple was limited in number, covering only 100 pregnent
women1,2. Therefore, in 2001 year, the study about drug
use in pregnancy was repeated on all pregnant women
who were admitted to the Department of Obstetrics and
Gynecology for delivery and to Genetics Counseling De-
partment at the Institute for Child and Youth Health
Care.
Administration of antibacterials during pregnancy is
very common3,4. It is well known that pharmacoepide-
miological studies dealing with prescription of drugs in
pregnancy are numerous5–7. Results showed, that only
exceptionally drugs that are used in pregnancy have been
proven teratogenic. However, little is known about subtle
effects of drugs on fetal development, particularly when
dealing with old drugs8–13.
According to the Food and Drug Administration all
drugs can be classified in 5 risk groups. Risk factors (A,
B, C, D and X) have been assigned to all drugs on the
level of risk the drug poses to the fetus. Risk factors are
designed to help the reader to classify quickly a drug for
use during pregnancy. They do not refer to breast feeding
risk. Drugs from category A and B are safe, drugs from
category C should be given only if the potential benefit
justifies the potential risk to the fetus, drugs from cate-
gory D should be given only in a life-treatening situation
or for a serious disease for which safer drugs cannot be
used or are ineffective. The risk of the use of the drugs
from category X in pregnant women clearly outweighs
any possible benefit14.
Penicillins and cephalosporins, according to FDA clas-
sification of drugs based on safety for the fetus belong to
category B. Therefore they belong to the most often used
drugs in pregnancy10,14–17. Nevertheless, some recent pa-
pers report presence of teratogenic potential of these
919
Received for publication June 20, 2007
drugs18–22. Therefore the aim of our study was to estab-
lish the possible correlation between use of antibacterial
drugs in pregnancy and occurrence of congenital malfor-
mations.
Materials and Methods
The data for this study were collected as a part of the
study analysing the teratogenicity of drugs used in preg-
nancy, a longitudinal study performed in Novi Sad dis-
trict, designed to investigate the potential teratogenicity
of the drugs.
The independent Ethics Committee of the Faculty of
Medicine, Novi Sad, approved the study. Pregnant wo-
men attending the Clinics of University Teaching Centre
in 2001 were eligible to be involved.
The study was performed from Jan 1st – Dec 31st 2001
and involved the women who terminated pregnancy for
medical reasons or delivered during the observed period.
Only women willing to participate in the study who
signed informed consent forms were included. All partici-
pating women were interviewed.
The sources of the data were:
¿ the questionnaires for pregnant women given by
the doctor during the hospitalization at the Depart-
ment of Gynecology and Obstetrics or at Genetics
Counseling Department
¿ detailed physical examination of newborn babies in
order to establish the presence of major or minor
malformations, examination performed according
to a standard protocol, done by trained pediatri-
cians
¿ pathophysical examination of fetuses performed ac-
cording to a standard protocol, done by trained pa-
thologists.
In the Department of Gynecology and Obstetrics and
in Genetics Counseling Department of Novi Sad, 6099
questionnaires were filled by pregnant women during
2001. The questionnaire, based on the questionnaire of
the year 1987, was designed at the Department of Phar-
macology, Toxicology and Clinical Pharmacology, Faculty
of Medicine in Novi Sad. Maternal data were collected
retrospectively by interviewing the participating women
before delivery. Questionnaires were fulfiled by a tra-
ined, highly qualified medical doctor. Information re-
quested on the questionnaire included mother’s data
(age, education, obstetrical history), and drug therapy, as
well as use of alcohol, caffeine, nicotine and narcotics
during pregnancy. Only the women who took antibiotics
during pregnancy were analysed. Altogether, 392 preg-
nant women were included in final analysis. After deliv-
ery or abortion, newborn and fetuses were analysed in
order to establish existence of minor or major malforma-
tions.
The use of antibacterials was analysed according to
their use in first, second or third trimester of pregnancy.
Antibacterials used by pregnant women were categorized
by risk of harmful effect on fetus in 5 categories accord-
ing to FDA.
Results
Out of the total number of pregnant women 2013
(33.00%) of them used medications (Figure 1).
All drugs used during pregnancy, and malformations
which were detected in their fetuses or newborns are pre-
sented in Table 1.
Out of the total number of pregnant women that used
medications during pregnancy (2013 pregnant women)
392 (19.5 %) used antibacterial drugs (Figure 2). Malfor-
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TABLE 1






fetuses or newborn n
(n/N)% (N/6099)% (n/6099)%
J 392 20 5.10 6.43 0.33
G 289 13 4.50 4.74 0.21
A 449 18 4.01 7.36 0.30
B 442 15 3.39 7.25 0.25
N 166 12 7.23 2.72 0.20
C 102 5 4.90 1.67 0.08
R 23 1 4.35 0.38 0.02
H 2 0 0 0.03 0
G* 536 28 5.22 8.79 0.46
D 5 0 0 0.08 0
M 22 1 4.55 0.36 0.02
J – drugs for infections, G – drugs for genitourinary disorders, A – drugs for alimentary tract disorders and metabolism, B – drugs for
blood disorders, N – drugs for CNS disorders, C – drugs for cardiovascular disorders, R – drugs for respiratory disorders, H – drugs for
hormonal disorders, G* – drugs for delivery and it's complications (Tocolitics), D – drugs for dermatological disorders, M – drugs for
musculosceletal disorders
mations were detected in 20 (5.1%) cases. The prevalence
of malformations in newborns whose mothers did not
take antibiotics in pregnancy was 5.4% (5707 pregnant
women; 306 newborns with malformations).
The use of antibacterial drugs in each trimester of
pregnancy was as follows: 44.6% in the first trimester,
21% in the second trimester and as much as 37.9% in the
third trimester (Figure 3).
The most frequently used antibacterial medications
were from category B (75,8%), while 14.5% antibiotics
belonged to category D and 1.0% to category X (Figure 4).
The most often used antibiotics were cephalexin (87
pregnant women), amoxicillin (81 pregnant women) and
ampicillin (56 pregnant women), all belonging to group
B. They were all used throughout pregnancy. Tetra-
cyclines, sulfonamides, aminoglycosides and quinolones,
which belonged to groups C (sulfonamide-trimethoprim
combinations, erythromycin estolate, ciprofloxacin, nor-
floxacin) and D (doxycycline, streptomycin, gentamicin),
were used in the first trimester of pregnancy. This period
is not harmful as the goal organs as not developed yet
(Table 2).







Fig. 1. Usage of medications during pregnancy.
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Fig. 3. Usage of antibacterial drugs in pregnancy by trimesters.
TABLE 2
ANTIBACTERIAL AGENTS USED BY PREGNANT WOMEN
Type of antibacterial




women using the drug
Trimester of pregnancy
I II III
TETRACYCLINES doxycycline J01AA02 41 41 – –
PENICILLINS
ampicillin J01CA01 56 18 12 32
amoxicillin J01CA04 81 32 27 43
penicillin G J01CE 43 10 17 21
amoxicillin, clavulanic acid J01CR02 12 8 3 4
CEPHALOSPORINS
cephalexin J01DA01 87 34 18 69
cefaclor J01DA08 10 8 1 4
ceftriaxone J01DA13 7 2 2 3
SULFONAMIDES sulfonamide- trimethoprim
combinations
J01EE01 13 13 – –
MACROLIDE
ANTIBIOTICS
erythromycin estolate J01FA01 11 11 – –
AMINOGLYCOSIDE
ANTIBIOTICS
streptomycin J01GA01 1 1 – –
gentamicin J01GB03 15 15 – –
QUINOLONES
ciprofloxacin J01MA02 9 9 – –
norfloxacin J01MA06 1 1 – –

































Fig. 4. Usage of antibacterial drugs during pregnancy and risk
from harmful effects on the fetus.
Malformations which were detected on fetuses ex-
posed to antibacterial drugs and trimester of exposure
are shown in Table 3. We detected one major malforma-
tion (hypospadias) in newborn exposed to amoxicillin
during the first trimester after conception. In this case,
additional teratogens were not detected.
The use of antibiotics together with another potential
teratogen during pregnancy is shown in Table 4.
Discussion
Stages of pregnancy that are critical with respect to
possible harmful effects of medications on the developing
fetus are still inexplicitly defined and potential risks of
drugs for mother and the fetus are faintly understood,
thus question of medication use during pregnancy still
remains a chronic and everlasting problem. A compre-
hensive monitoring of the use of medicines in a particu-
lar environment over a long period of time can decrease
the risk of harmful effects of drugs during pregnancy
through proper evaluation of pharmacotherapy during
pregnancy, and if necessary, through appropriate educa-
tional measures towards improvement of pharmacothe-
rapeutical practice.
Drug prescribing for pregnant women has been moni-
tored in Novi Sad since 1987, when, in the framework of
international Collaborative Study on Drug Use in Preg-
nancy (DUP), the investigation included 296 pregnant
women. The second pilot study, encompassing 100 preg-
nant women was conducted in 1999, and in 2001 the
third, by now the longest study performed, which lasted
during the whole year 20011,2,26.
Penicillins and cephalosporins were the most fre-
quently used antibiotics during pregnancy. Beta-lactam
antibiotics are widely used because of their lack of toxic-
ity in humans. However, during pregnancy, exposure of
the fetus is likely to occur because beta-lactam antibiot-
ics cross the placenta18. From previous data, it is unlikely
that penicillins and cephalosporins are teratogenic14. Only
one reference has linked the use of penicillin G with con-
genital abnormalities: an examination of hospital records
indicated that in three of four cases the administration of
penicillin G had been followed by birth of a malformed
baby. However, due to uncompleted analysis of the data
no causal relationship to penicillin G could be shown19,20.
According to Briggs (1998), the use of ampicillin in early
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doxycycline D 1 diastasis of rectal abdominal muscle 1 – –
ampicillin
B 3











syndactyli of the 2nd and 3rd
toe in both feet, four fingers line,




B 1 right ear flap 1 – –
cephalexin
B 2





syndactyli of the 2nd and 3rd
toe of the left foot
1 – –




C (D in 3/3) 2
hydronephrosis of both kidneys,




C 0 – – – –
streptomycin D 0 – – – –
gentamicin
D 2
cyst of choroid plexus, talipes
valgus of both feet
2 – –
ciprofloxacin C 1 cyst of choroid plexus 1 – –
norfloxacin C 0 – – – –
metronidazole B (X in 1/3) 0 – – – –
pregnancy was associated with a prevalence ratio esti-
mate of 3.3 for congenital heart disease in a retrospective
study14. A specific defect, transposition of the great arter-
ies, had a risk of 7.7 based on exposure in 2 of the 29 in-
fants with anomaly. The investigators did note that the
results had to be viewed cautiously because the data
were subject to recall bias (drug histories were taken by
questionnaire or telephone up to one year after pre-
sumed exposure) and the study could not distinguish be-
tween the fetal effects of the drug versus those of the in-
fectious agent for which the drugs were used21. The
prenatal administration of amoxicillin on fetuses of mice
at doses of 500 or 650 mg/kg body weight resulted in both
teratogenic and toxic effects on fetuses of treated moth-
ers. Such effects comprised the development of abnormal
hindlimbs and tails. The drug was safe to treated dams at
all dose levels and at all times during gestation22. In
young rats exposed to ampicillin and amoxicillin in utero,
a mild oligonephronia was present and cystic tubule dila-
tion was observed in newborn and in young animals as
well18.
In our study 192 pregnant women used penicillins.
Malformations were detected in 11 fetuses (5.7%). In
newborns exposed to ampicillin activity in utero short
lingual frenulum in 2 and right ear flap in 1 newborn
were detected. Out of the 3 newborns which were born
with minor malformations, 1 was exposed to X-rays dur-
ing the preconception period. However, this X-ray exposi-
tion is probably not the cause of minor malformation
that we detected. In newborns exposed to amoxicillin ac-
tivity in utero short lingual frenulum (1 newborn), hypo-
spadias (1 newborn), talipes valgus of the right foot (1
newborn) and micrognathia (1 newborn) were detected.
These newborns were not exposed to another potential
teratogens. The results show possible teratogenic poten-
tial of amoxicillin. In newborns exposed to penicillin G
activity in utero syndactyli of the 2nd and 3rd toe in both
feet (1 newborn), four fingers line (1 newborn) and cyst
of choroid plexus (1 newborn) were detected.
Several published reports have described the adminis-
tration of cephalosporins to pregnant patients in various
stages of gestation23,24. None of these have linked the use
of cephalosporins with congenital defects or toxicity in
the newborn14,25,26.
In our study 104 pregnant women used cephalospo-
rins. Malformations were detected in 3 newborns (2.9%).
In newborns exposed to cephalexin activity in utero, cyst
of choroid plexus (1 newborn) and short lingual frenu-
lum (1 newborn) were detected. One newborn with short
lingual frenulum was exposed to X-rays during the first
trimester after conception. X-ray exposure could theoret-
ically contribute to appearance of the malformation. In 1
newborn exposed to cefaclor activity in utero, syndactyli
of the 2nd and 3rd toe of the left foot was detected. This
newborn was not exposed in utero to other potential
harmful factors.
Tetracyclines are a class of antibiotics that should be
used with extreme caution, if at all, in pregnancy. Prob-
lems attributable to the use of the tetracyclines during
the gestational period can be classified into four areas:
adverse effects on fetal teeth and bones, maternal liver
toxicity, congenital defects and miscellaneous effects. Te-
tracycline forms a complex with calcium orthophosphate
and becomes incorporated into bones and teeth undergo-
ing calcification. In the latter structure, this complex
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TABLE 4




Use with another potential teratogen
Findings on fetuses
and newborns
doxycycline I 3 women older than 35 years negative
ampicillin
II 1 HB positive woman jaundice precocious
II
1 woman with pneumonia,
1 woman older than 35 years
negative
I 1 woman exposed to X-ray right ear flap
penicillin G
III
2 women who smoked up to
10 cigarettes per day
negative
II 1 woman with pneumonia negative
I, III 2 women older than 35 years negative
cephalexin
I 1 woman was exposed to X-ray short lingual frenulum
III contact with varicella (chickenpox) negative
III 2 women older than 35 years negative
ceftriaxone I 1 woman was exposed to X-ray negative
erythromycin estolate I 1 woman was exposed to X-ray negative
streptomycin I 1 woman was exposed to X-ray negative
gentamicin
I
1 woman who smoked up to
10 cigarettes per day
cyst of choroid plexus
ciprofloxacin I 1 woman was exposed to X-ray negative
causes a permanent discoloration, as remodeling and cal-
cium exchange do not occur after calcification is com-
pleted. Because the deciduous teeth begin to calcify at
around 5 or 6 month in utero, use of tetracycline after
this time will result in staining. They belong to category
D, regarding harmful effects on the fetus14,27.
In our study 41 pregnant women used tetracyclines,
most of them in the first trimester. Malformations were
detected in 1 newborn (2.4%). It was a minor malforma-
tion, diastasis of rectal abdominal muscle and the new-
born was not exposed in utero to another known poten-
tial teratogen.
Sulfonamides belong to category B regarding harmful
effects on the fetus during the first and second trimester
and to category D during the third trimester. Sulfona-
mides are teratogenic in some species of animals, a find-
ing that has prompted warnings of human teratogenicity.
Investigators associated in utero sulfonamide exposure
with tracheoesophageal fistula, cataracts, ductus arte-
riosus persistens, hypoplasia of limb, miscellaneous foot
defects, urethral obstruction, hypoplasia or atrophy of
adrenals, hypospadias28–30. Combination of sulfonamide
and trimethoprim, co-trimoxasole (category C), shouldn’t
be used during pregnancy due to the activity of tri-
methoprime in the metabolism of folates31,32.
In our study 13 pregnant women used sulfonamides.
Malformations were detected in 2 fetuses (15.4%). We de-
tected hydronephrosis of both kidneys in 1 fetus and cyst
of choroid plexus in 1 newborn. In these cases exposition
to other potential teratogens during pregnancy was not
detected.
Aminoglycosides may cause side effects in the fetus
and in mother when given in pregnancy, so they should
be used in pregnancy only in exceptional situations when
other antibiotics are not efficient or cannot be applied.
They belong to category D regarding harmful effects on
the fetus. Eighth cranial nerve toxicity in the fetus is
well known following exposure to aminoglycosides like
streptomycin andmay potentially occur with gentamicin14.
In our study 16 pregnant women used aminoglyco-
sides. All examined pregnant women used gentamicin
and streptomycin in the first weeks of pregnancy, which
is not a harmful period. Malformations were detected in
2 newborns (12.5%). In newborns exposed to gentamicin
activity in utero, a cyst of choroid plexus (1 newborn) and
talipes valgus of both feet (1 newborn) were detected.
The newborn with the cyst of choroid plexus was exposed
to nicotine (his mother smoked up to 10 cigarettes per
day during the first trimester).
The use of quinolones during pregnancy does not ap-
pear to be associated with an increased risk of major con-
genital malformations. Although a number of birth de-
fects have occurred in the offspring of women who had
taken this drug during pregnancy, the lack of a pattern
among the anomalies is reassuring. However, a causal re-
lationship with some of the birth defects cannot be ex-
cluded. A 1993 review on the safety of fluoroquinolones
confirmed that these antibacterials should be avoided
during pregnancy because of the difficulty in extrapolat-
ing animal mutagenicity results to humans and because
interpretation of this toxicity is still controversial33. The
authors of this review were not convinced that fluoro-
quinolones induced fetal cartilage damage and subse-
quent arthropathies were a major concern, even though
this effect had been demonstrated in several animal spe-
cies after administration to both pregnant and immature
animals and in occasional human case reports involving
children. Others have also concluded that fluoroquino-
lones should be given with extreme caution, because
safer alternatives are usually available34.
In our study 10 pregnant women used quinolone anti-
biotics. All examined pregnant women used medications
from this group in the first weeks of pregnancy. Malfor-
mations were detected in 1 newborn (10%). In newborns
exposed to ciprofloxacin activity in utero, a cyst of cho-
roid plexus (1 newborn) was detected. The newborn was
not exposed to another teratogen in pregnancy.
The available reports have arrived at conflicting con-
clusions on the safety of metronidazole in pregnancy35.
In our study 5 pregnant women used nitroimidazoles.
Malformations were not detected in their fetuses.
Analysis of antibiotic prescribing in the period 1989–
2002 revealed a distinct decreasing tendency. Such
trends of reduction of drugs during pregnancy strongly
suggest that healthcare providers, as well as their pa-
tients, are aware of potential risks of medications for
pregnancy and development of the fetus. It is well estab-
lished that first-trimester exposure to drugs is critical for
the fetus. At advanced stages of pregnancy most of the
drugs may result in individual minor malformations.
Thus, abandonment of particular medication after first
or second trimester does not necessarily imply ceasing of
its potential harmful effects on the fetus, mother or preg-
nancy course. All this emphasized the need for urgent ed-
ucational efforts aimed at instructing medical profes-
sionals, as well as the women in reproductive period. The
scope of such education is threefold, i.e.: 1. the pregnancy
should be planned whenever possible 2. in all cases when
monthly period is late, if possible within the »all-or-noth-
ing« period (the first 21 days of pregnancy) it is necessary
to confirm pregnancy, and if so, withdraw the use of all
medications; and 3. healthcare providers should take
into account that all their patients may be pregnant,
thus the therapy of choice should include medications
from the group B or at least C, as well as continuous
monitoring of the patient’s health status.
Conclusions
According to our investigation pregnant women most
frequently used antibacterial agents in the first trimes-
ter of pregnancy (207 pregnant women; 52.8 %). They
used 15 different antibacterial medications, most often
beta lactam antibiotics: cephalexin – 87 pregnant women
(22.2 %); amoxicillin – 81 pregnant women (20.7 %);
ampicillin – 56 pregnant women (14.3 %); penicillin G –
43 pregnant women (11.0 %). The most frequently used
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antibacterial were drugs from category B according to
harmful effects to the fetus (297 pregnant women; 75.8
%). The prevalence of malformations in newborns whose
mothers did not take antibiotics in pregnancy was 5.4%
and the prevalence of malformations in newborns whose
mothers did take antibiotics in pregnancy was 5.1%. In
20 embryos exposed to effects of antibacterials in utero
malformations were detected (19 minor, 1 major malfor-
mations). Ten fetuses/newborns with minor malforma-
tions and one with a major malformation were exposed
in utero to penicillins, that is 5.7% of the total number of
fetuses exposed to penicillins. Short lingual frenulum
was detected in 3 cases, additional teratogens were not
detected. In publications up to now, these malformations
have not been described as a result of the use of penicil-
lins in pregnant women. The results of this study show
possible teratogenic potential even with those antiba-
cterials which are considered safe (amoxicillin-hypospa-
dias), but as those are usually minor malformations they
often pass undetected. Because of that and because of
frequent use of antibacterials during pregnancy, detailed
examinations concerning their safety should be made.
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TERATOGENOST ANTIBAKTERIJSKIH LIJEKOVA
S A @ E T A K
Cilj na{e studije bio je utvrditi mogu}u povezanost izme|u uporabe antibakterijskih lijekova u trudno}i i u~estalosti
kongenitalnih malformacija. Od 6099 ispitivanih trudnica, 392 (6,43%) su koristile antibakterijske lijekove. Naj~e{}e su
rabljeni antibakterijski lijekovi koji pripadaju kategoriji B (75,77%), dok je 14,54% antibiotika pripadalo kategoriji D, a
1,02% kategoriji X. Naj~e{}e rabljeni antibiotici bili su cefaleksin (22,19%), amoksicilin (20,66%) i ampicilin (14,29%).
Malformacije su dijagnosticirane kod 14 plodova koji su in utero bili izlo`eni djelovanju beta-laktamskih antibiotika.
Rezultati ove studije ukazuju na mogu} teratogeni potencijal antibakterijskih lijekova koji se smatraju sigurnim, ali
kako se ve}inom radi o minor malformacijama, one ~esto ostaju nezapa`ene. Zbog toga i zbog ~este uporabe antibakte-
rijskih lijekova u trudno}i, potrebno je sprovesti detaljna istra`ivanja o sigurnosti njihove primjene.
M. Eri} et al.: Antibacterial agents, Coll. Antropol. 32 (2008) 3: 919–925
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